Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01488019 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)
A Phase 4 study, sponsored by Dey.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,071
- Enrollment target
NCT01488019 is a Phase 4 study that has completed, run by Dey. The registered enrollment target is 1,071 participants.
The verdict
NCT01488019, a Phase 4 study, has completed, sponsored by Dey.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,071 participants
- Enrollment target
Study Summary
This study is a multi-center, randomized, placebo-controlled study to evaluate the long-term safety of Perforomist® inhalation therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD). Individual participation is approximately 54 weeks, including 52 weeks of double-blind treatment.
Interventions
- DRUG Perforomist-Placebo
- DRUG Perforomist, nebulization, COPD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,071 participants |
| Start Date | 2012-03 |
| Est. Completion | 2016-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01488019
The ClinicalTrials.gov registry entry for NCT01488019 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,071 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dey, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Perforomist-Placebo is the first listed.
NCT01488019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01488019 about?
NCT01488019 is a clinical study titled "Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)". This study is a multi-center, randomized, placebo-controlled study to evaluate the long-term safety of Perforomist® inhalation therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD). Individual participation is approximately 54 weeks, including 52 weeks of double-blind treatment.
What is the current status of trial NCT01488019?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,071 participants. The study started on 2012-03. Estimated completion is 2016-01.
What interventions are being tested in trial NCT01488019?
The interventions under investigation include: Perforomist-Placebo (DRUG), Perforomist, nebulization, COPD (DRUG).
Who is sponsoring clinical trial NCT01488019?
This trial is sponsored by Dey, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.